Dgci

Dgci News

Government panel recommends permission for phase 3 trial of Sputnik Light vaccine as booster dose
India

Government panel recommends permission for phase 3 trial of Sputnik Light vaccine as booster dose

The DCGI had on 4 February granted emergency use permission to Sputnik Light vaccine in India, subject to certain regulatory provisions

Sputnik Light, J&J take another step towards joining India's COVID vaccine arsenal
India

Sputnik Light, J&J take another step towards joining India's COVID vaccine arsenal

While Sputnik Light has received DCGI's approval for phase-3 bridging trials, around 35 lakh doses of J&J’s vaccine have been dispatched for final round of quality and safety checks in HP

Kolkata hospital awaits DGCI nod to begin Phase 2 trial of Russia's Sputnik V COVID-19 vaccine
India

Kolkata hospital awaits DGCI nod to begin Phase 2 trial of Russia's Sputnik V COVID-19 vaccine

The RDIF has also partnered with Dr Reddy's Lab to supply 100 million doses of its COVID-19 vaccine in development.

Covaxin, Bharat Biotech's COVID-19 vaccine candidate, gets DCGI nod for Phase 3 trials
India

Covaxin, Bharat Biotech's COVID-19 vaccine candidate, gets DCGI nod for Phase 3 trials

The phase 3 trials will be conducted in 19 sites across 10 states, including in cities such as Delhi, Mumbai, Patna and Lucknow and would seek to enroll 28,500 volunteers aged 18 years and above.

Oxford COVID-19 vaccine: Panel recommends that DCGI grant Serum Institute permission for human trials
India

Oxford COVID-19 vaccine: Panel recommends that DCGI grant Serum Institute permission for human trials

The DCGI had earlier asked SII to clearly define Phase 2 and Phase 3 of trials and resubmit their application for evaluation.

COVID-19 treatment: Fabiflu by Glenmark, HCQ, Remdesivir and other drugs that are being used to treat coronavirus patients
India

COVID-19 treatment: Fabiflu by Glenmark, HCQ, Remdesivir and other drugs that are being used to treat coronavirus patients

Favipiravir is an antiviral drug which was developed by a Japanese pharma company, Fujifilm Toyama Chemical, to treat influenza.

GJEPC denies four-fold surge in imports of cut and polished diamonds, says there has actually been a 4.3% decline
Business

GJEPC denies four-fold surge in imports of cut and polished diamonds, says there has actually been a 4.3% decline

Actual imports of cut and polished diamonds for this period stand at $1,527.43 million, and represent a decline of 14.44 percent as compared to $1,785.17 million for April-November 2016.

Biocon reports Q3 net profit of Rs 105 cr, up 14%
Biztech

Biocon reports Q3 net profit of Rs 105 cr, up 14%

The key highlight was the DCGI approval for our biosimilar Trastuzumab, which paved the way for its commercial launch in India as CANMAb.<br /><br />